Abstract:
Introduction: The presence of background HCV
infection cannot be overestimated in view of the prevalence
of chronic hepatitis C and the risk of adverse outcomes
of this disease. Purpose of this study was to evaluate
the effectiveness of the combined use of antiviral therapy
(Roferon + Vero-Ribavirin) and resort factors in patients
with chronic hepatitis C in the phase of replication.
Material and methods: We observed 48 patients with
chronic hepatitis C; the minimum level of activity of the
process defined the phase of replication. Markers of HCV
infection were determined by enzyme linked immunosorbent
assay (ELISA) (a-HCV and HCV-Ig M). HCV RNA
was determined twice by the polymerase chain reaction
(PCR). Genotyping of hepatitis C virus was performed.
Biochemical blood analysis and the study of HCV infection
markers were carried out four times. Results of therapy
were assessed immediately after the end of the resort
(spa) treatment, then at 3, 6 and 12 months after starting
treatment. At 12 months after starting treatment, all the
observed patients had persistent clinical and biochemical
remission. Elimination of the virus from the blood was
noted in 56% of the control group and 74% of patients in
the study group.
Conclusions: For patients with moderately active HCV, the
replication phase was characterized by asthenic-vegetative
syndrome (100% of patients) with severe depression (22.92%), pain (77.08%) and dyspeptic syndrome (33.33%),
moderate hypertransferaseemia (100%), slightly pronounced
cholestasis (33% of patients), and signs of mesenchymal-
inflammatory response.
